Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

Eli Magen; Sumit Mukherjee; Mahua Bhattacharya; Rajesh Detroja; Eugene Merzon; Idan Blum; Alejandro Livoff; Mark Shlapobersky; Gideon Baum; Ran Talisman; Evgenia Cherniavsky; Amir Dori; Milana Frenkel-Morgenstern

doi:10.3390/vaccines10071135

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

Eli Magen, Sumit Mukherjee, Mahua Bhattacharya, Rajesh Detroja, Eugene Merzon, Idan Blum, Alejandro Livoff, Mark Shlapobersky, Gideon Baum, Ran Talisman, Evgenia Cherniavsky, Amir Dori, Milana Frenkel-Morgenstern

Bar-Ilan University - Azrieli Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after injection of the first dose of BNT162b2 COVID-19 mRNA vaccine into the left deltoid muscle of a 34-year-old, previously healthy woman who presented progressive proximal muscle weakness, progressive dysphagia, and dyspnea with respiratory failure. One month after vaccination, BNT162b2 vaccine mRNA expression was detected in a tissue biopsy of the right deltoid and quadriceps muscles. We propose this case as a rare example of COVID-19 mRNA vaccine-induced myositis. This study comprehensively characterizes the clinical and molecular features of BNT162b2 mRNA vaccine-associated myositis in which the patient was severely affected.

Original language	English
Article number	1135
Journal	Vaccines
Volume	10
Issue number	7
DOIs	https://doi.org/10.3390/vaccines10071135
State	Published - 16 Jul 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

Funding

The authors thank members of the Cancer Genomics and Biocomputing of Complex Diseases Lab for multiple discussions at different stages of this project. S.M. was supported by the Israeli Council of Higher Education and Research through the PBC fellowship program for outstanding postdoctoral researchers from China and India (2019–2021). M.F-M. was supported by the COVID-19 Data Science Institute (DSI) grant, Bar-Ilan University (#247017, 2020).

Funders	Funder number
COVID-19 Data Science Institute
Israeli Council of Higher Education and Research
Bar-Ilan University	247017
Defence Science Institute

Keywords

BNT162b2
COVID-19
mRNA vaccine
myositis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines10071135

Cite this

Magen, E., Mukherjee, S., Bhattacharya, M., Detroja, R., Merzon, E., Blum, I., Livoff, A., Shlapobersky, M., Baum, G., Talisman, R., Cherniavsky, E., Dori, A., & Frenkel-Morgenstern, M. (2022). Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis. Vaccines, 10(7), Article 1135. https://doi.org/10.3390/vaccines10071135

@article{90ed1e997742482aba2e733eccc33916,

title = "Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis",

abstract = "Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after injection of the first dose of BNT162b2 COVID-19 mRNA vaccine into the left deltoid muscle of a 34-year-old, previously healthy woman who presented progressive proximal muscle weakness, progressive dysphagia, and dyspnea with respiratory failure. One month after vaccination, BNT162b2 vaccine mRNA expression was detected in a tissue biopsy of the right deltoid and quadriceps muscles. We propose this case as a rare example of COVID-19 mRNA vaccine-induced myositis. This study comprehensively characterizes the clinical and molecular features of BNT162b2 mRNA vaccine-associated myositis in which the patient was severely affected.",

keywords = "BNT162b2, COVID-19, mRNA vaccine, myositis",

author = "Eli Magen and Sumit Mukherjee and Mahua Bhattacharya and Rajesh Detroja and Eugene Merzon and Idan Blum and Alejandro Livoff and Mark Shlapobersky and Gideon Baum and Ran Talisman and Evgenia Cherniavsky and Amir Dori and Milana Frenkel-Morgenstern",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = jul,

day = "16",

doi = "10.3390/vaccines10071135",

language = "אנגלית",

volume = "10",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

TY - JOUR

T1 - Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

AU - Magen, Eli

AU - Mukherjee, Sumit

AU - Bhattacharya, Mahua

AU - Detroja, Rajesh

AU - Merzon, Eugene

AU - Blum, Idan

AU - Livoff, Alejandro

AU - Shlapobersky, Mark

AU - Baum, Gideon

AU - Talisman, Ran

AU - Cherniavsky, Evgenia

AU - Dori, Amir

AU - Frenkel-Morgenstern, Milana

PY - 2022/7/16

Y1 - 2022/7/16

N2 - Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after injection of the first dose of BNT162b2 COVID-19 mRNA vaccine into the left deltoid muscle of a 34-year-old, previously healthy woman who presented progressive proximal muscle weakness, progressive dysphagia, and dyspnea with respiratory failure. One month after vaccination, BNT162b2 vaccine mRNA expression was detected in a tissue biopsy of the right deltoid and quadriceps muscles. We propose this case as a rare example of COVID-19 mRNA vaccine-induced myositis. This study comprehensively characterizes the clinical and molecular features of BNT162b2 mRNA vaccine-associated myositis in which the patient was severely affected.

AB - Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after injection of the first dose of BNT162b2 COVID-19 mRNA vaccine into the left deltoid muscle of a 34-year-old, previously healthy woman who presented progressive proximal muscle weakness, progressive dysphagia, and dyspnea with respiratory failure. One month after vaccination, BNT162b2 vaccine mRNA expression was detected in a tissue biopsy of the right deltoid and quadriceps muscles. We propose this case as a rare example of COVID-19 mRNA vaccine-induced myositis. This study comprehensively characterizes the clinical and molecular features of BNT162b2 mRNA vaccine-associated myositis in which the patient was severely affected.

KW - BNT162b2

KW - COVID-19

KW - mRNA vaccine

KW - myositis

UR - http://www.scopus.com/inward/record.url?scp=85136086794&partnerID=8YFLogxK

U2 - 10.3390/vaccines10071135

DO - 10.3390/vaccines10071135

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35891299

AN - SCOPUS:85136086794

SN - 2076-393X

VL - 10

JO - Vaccines

JF - Vaccines

IS - 7

M1 - 1135

ER -

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this